Prentiss Smith & Co’s Immunogen Inc IMGN Stock Holding History

Prentiss Smith & Co’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$9K	–	242
2018 Q3	$9K	Hold	1,000	–	–	0.01%	216
2018 Q2	$10K	Hold	1,000	–	–	0.01%	212
2018 Q1	$11K	Hold	1,000	–	–	0.01%	217
2017 Q4	$6K	Hold	1,000	–	–	﹤0.01%	246
2017 Q3	$8K	Hold	1,000	–	–	﹤0.01%	208
2017 Q2	$7K	Hold	1,000	–	–	﹤0.01%	215
2017 Q1	$4K	Hold	1,000	–	–	﹤0.01%	221
2016 Q4	$2K	Hold	1,000	–	–	﹤0.01%	249
2016 Q3	$3K	Hold	1,000	–	–	﹤0.01%	235
2016 Q2	$3K	Hold	1,000	–	–	﹤0.01%	247
2016 Q1	$9K	Hold	1,000	–	–	0.01%	240
2015 Q4	$14K	Hold	1,000	–	–	0.01%	216
2015 Q3	$10K	Hold	1,000	–	–	0.01%	225
2015 Q2	$14K	Hold	1,000	–	–	0.01%	198
2015 Q1	$9K	Hold	1,000	–	–	﹤0.01%	241
2014 Q4	$6K	Hold	1,000	–	–	﹤0.01%	267
2014 Q3	$11K	Hold	1,000	–	–	0.01%	189
2014 Q2	$12K	Hold	1,000	–	–	0.01%	189
2014 Q1	$15K	Hold	1,000	–	–	0.01%	190
2013 Q4	$15K	Hold	1,000	–	–	0.01%	182
2013 Q3	$17K	Hold	1,000	–	–	0.01%	175
2013 Q2	$17K	Buy	+1,000	New	+$16.2K	0.01%	175

Other funds holding IMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prentiss Smith & Co's IMGN Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Immunogen Inc (IMGN) in Q4 2018, closing a stake of 1,000 shares — an estimated $9K sold.

Prentiss Smith & Co first reported a position in IMGN in Q2 2013 and held it in 22 quarters. The position peaked at $17K in Q3 2013. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2018.

Prentiss Smith & Co reported no remaining Immunogen Inc position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 1,000 Immunogen Inc shares in Q4 2018, an estimated $9K.
Prentiss Smith & Co first reported a position in Immunogen Inc in Q2 2013 and held it in 22 quarters.
Prentiss Smith & Co's Immunogen Inc position peaked at $17K in Q3 2013.
200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.